Medigus’ MUSE System Continues to Gain Clinical Adoption in the U.S. and Europe, With Number of Procedures Up Three-Fold Over Same Period Last Year

OMER, Israel, March 1, 2016 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced today that several commercial procedures using the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, have been completed by leading gastroenterologists in Europe and the U.S. Since the product’s introduction, more than 200 procedures have been performed globally using MUSE. Recently, Dr. Ali Lankarani, Board member of the Advanced Therapeutic Endoscopy Center (ATEC) at the Borland-Groover Clinic in Jacksonville, FL, completed his eighteenth procedure with the MUSE system.

“In my experience, MUSE offers many advantages over existing therapies and should be considered by gastroenterologists as a leading minimally-invasive treatment option for their GERD patients,” said Dr. Lankarani. “Transoral fundoplication, the procedure performed with the MUSE system, addresses the underlying cause of GERD and therefore delivers long-term relief from its painful symptoms while also offering greater patient comfort over more invasive procedures.”

MUSE is a comprehensive device incorporates microvisual, ultrasonic and surgical stapling capability. The device allows a single physician or surgeon to perform fundoplication (stapling of the upper part of the stomach to the lower esophageal sphincter) transorally (without incisions). Since the device doesn’t require any incisions, patients generally report greater comfort during procedure and experience reduced hospital stays by up to 50% over invasive fundoplication procedures.

Medigus’ flagship medical device continues to gain adoption from leading physicians and healthcare centers around the world. Year to date, nearly 25 procedures using the MUSE system have been completed by top physicians in markets where the device is commercially available, including:
• Barham K. Abu Dayyeh, MD, Gastroenterologist, Mayo Clinic, Minnesota
• Professor Thomas Rösch, Director of the Clinic for Interdisciplinary Endoscopy, University Medical Center Hamburg-Eppendorf and deputy publisher of Gut, a leading international journal in gastroenterology and hepatology
• Professor Guido Costamagna, Director of the Division of Digestive Endoscopy, Gemelli Hospital of the Catholic University in Rome
• Professor Pier Alberto Testoni, Chair of Gastroenterology and the Graduate School of Gastroenterology, University Vita-Salute San Raffaele University in Milan

“MUSE was designed to offer physicians and patients an advanced, competitive product for the treatment of GERD, and we thank these esteemed physicians for their continued support and ongoing advocacy to help drive its clinical adoption by educating their peers on its availability,” said Chris Rowland, CEO of Medigus.